ANL - Adlai Nortye Ltd. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

ANL

ADLAI NORTYE LTD.

NASDAQ

$13.82

▼ DOWN 3.49% (-0.50)

KEY STATISTICS

Market Cap$733.57 M

52w High$17.25

52w Low$0.88

Dividend Yield—

Frequency—

P/E-9.94

Volume165.03K

Shares Out.53.08M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Yang Lu

ABOUT

SECTOR

Healthcare

WENT PUBLIC

September 29, 2023

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

109

PRICE TARGET

Target High$32.00

Target Low$20.00

Target Median$26.00

Target Consensus$26.00

UPCOMING EARNINGS

DateMar 3, 2027

DayWednesday

Rev. Est.$3.66M

MAR

WED

PRICE

$13.82 ▼ DOWN 3.49% (−$0.50)

About Adlai Nortye Ltd.

https://www.adlainortye.com ↗

Adlai Nortye Ltd. is a clinical-stage biotech developing cancer therapies, including AN2025 (Phase III PI3K inhibitor), AN0025 (Phase Ib PGE2 receptor antagonist), and AN4005 (Phase I PD-L1 inhibitor), with several preclinical candidates.

INDUSTRY

Biotechnology

A PRODUCT ADLAI NORTYE LTD. IS KNOWN FOR

AN9025

AN9025 is an oral pan-RAS(ON) inhibitor in Phase 1 trials for RAS-mutant solid tumors, with Adlai Nortye focusing on its development after discontinuing Buparlisib, backed by $140M funding and a Greater China licensing deal.